REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.65
-0.07 (-0.80%)
At close: Mar 6, 2026, 4:00 PM EST
9.95
+1.30 (15.03%)
After-hours: Mar 6, 2026, 7:59 PM EST
REGENXBIO Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 29, with a low estimate of 12 and a high estimate of 50. The average target predicts an increase of 235.26% from the current stock price of 8.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 4 | 3 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +96.53% | Mar 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $34 → $32 | Strong Buy | Maintains | $34 → $32 | +269.94% | Feb 10, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +38.73% | Feb 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $25 → $18 | Buy | Maintains | $25 → $18 | +108.09% | Feb 10, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 → $50 | Strong Buy | Maintains | $52 → $50 | +478.03% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
270.65M
from 170.44M
Increased by 58.79%
Revenue Next Year
351.15M
from 270.65M
Increased by 29.74%
EPS This Year
-2.68
from -3.76
EPS Next Year
-2.04
from -2.68
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 408.5M | 522.3M | |||
| Avg | 270.7M | 351.2M | |||
| Low | 130.8M | 155.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 139.6% | 93.0% | |||
| Avg | 58.8% | 29.7% | |||
| Low | -23.3% | -42.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.69 | -0.67 | |||
| Avg | -2.68 | -2.04 | |||
| Low | -4.63 | -2.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.